Cytological or Histologically confirmed diagnosis of PC
Histologically or radiologically confirmed diagnosis of metastatic disease and
For ARON-3S
▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)
For ARON-3Lu
▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC
For ARON-3GEN
HRD POSITIVE STATUS
Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
For ARON-3Lu
▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC
For ARON-3GEN
HRD NEGATIVE STATUS
Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
You may not be if
Patients without histologically confirmed diagnosis of PC
Patients without histologically or radiologically confirmed metastatic disease and
For ARON-3S
Clareo Health | ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
